Monte Rosa Therapeutics (NASDAQ:GLUE) COO Jennifer Champoux Sells 2,175 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) COO Jennifer Champoux sold 2,175 shares of the company’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the sale, the chief operating officer directly owned 62,371 shares in the company, valued at $1,247,420. This trade represents a 3.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Monte Rosa Therapeutics Trading Up 1.1%

Shares of GLUE opened at $19.39 on Friday. The stock has a market capitalization of $1.64 billion, a P/E ratio of -13.10 and a beta of 1.62. The firm’s fifty day simple moving average is $18.12 and its two-hundred day simple moving average is $18.16. Monte Rosa Therapeutics, Inc. has a 12 month low of $3.90 and a 12 month high of $25.77.

Get Monte Rosa Therapeutics alerts:

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The company had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. As a group, research analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on GLUE shares. Wells Fargo & Company cut their price objective on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. JPMorgan Chase & Co. increased their price objective on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Guggenheim cut their price objective on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Finally, Zacks Research cut shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 4th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.50.

View Our Latest Report on GLUE

Institutional Investors Weigh In On Monte Rosa Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC acquired a new stake in shares of Monte Rosa Therapeutics in the 4th quarter worth about $30,000. Nisa Investment Advisors LLC increased its stake in Monte Rosa Therapeutics by 16.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after buying an additional 451 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Monte Rosa Therapeutics by 32.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after buying an additional 776 shares during the last quarter. Seven Fleet Capital Management LP purchased a new stake in Monte Rosa Therapeutics in the 4th quarter valued at about $63,000. Finally, Russell Investments Group Ltd. purchased a new stake in Monte Rosa Therapeutics in the 3rd quarter valued at about $32,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

(Get Free Report)

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.

Featured Stories

• Five stocks we like better than Monte Rosa Therapeutics
• Wall Street Is Starting to Talk About Tesla’s Endgame
• Meta’s Manus Mess: Why China Blocked the Deal and What It Means
• China Deal Ignites Boeing’s Financial Afterburners
• 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?

Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.